Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Metastatic × aldesleukin × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 20 Breast Neoplasms 10 Uterine Cervical Neoplasms 9 Pancreatic Neoplasms 8 Melanoma 7 Carcinoma, Non-Small-Cell Lung 7 Colorectal Neoplasms 6 Neoplasm Metastasis 5 Fallopian Tube Neoplasms 5 Stomach Neoplasms 4 Lung Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Vaginal Neoplasms 3 Urogenital Neoplasms 3 Small Cell Lung Carcinoma 3 Sarcoma 3 Penile Neoplasms 3 Oropharyngeal Neoplasms 3 Kidney Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Renal Cell 3 Anus Neoplasms 3 Vulvar Neoplasms 2 Triple Negative Breast Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Testicular Neoplasms 2 Testicular Germ Cell Tumor 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Papillomavirus Infections 2

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡